Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer

Chinese Medical Journal

Volumn 124, Issue 24, 2011, Pages 4345-4349

  Zhang, Yi Fen ^a   Guan, Yang Bo ^a,b   Yang, Bin ^a,c   Wu, Hong Yan ^a   Dai, Yu Tian ^a   Zhang, Shuang Jie ^a   Wang, Ji Ping ^d   Anoopkumar Dukie, Shailendra ^e   Davey, Andrew K ^e   Sun, Ze Yu ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

Author keywords

Clinical tumor node metastases stage; Gleason score; Her 2 neu protein; Prognosis; Prostate neoplasm

Indexed keywords

ANTIANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 84862939348     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.24.038     Document Type: Article

References (15)

1. Gu F. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J 2003; 116: 1391-1393.
2. Na YQ. Are we ready for prostate cancer? Chin Med J 2008; 121: 291.
3. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 1998; 52: 43-53.
4. Ratan HL, Gescher A, Steward WP, Mellon JK. ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 2003; 92: 890-895.
5. Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, et al. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer 2008; 123: 2636-2643.
6. Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, et al. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol 2010; 184: 842-850.
7. Prostate. In: Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Handbook. New York: Springer; 2009: 525-538.
8. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
9. Li CY, Liu HY, Lang JH, Wang HQ, Fan XL. Increased expression of stathmin in eutopic endometrium of patients with endometriosis. Chin Med J 2010; 123: 2190-2194.
10. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006; 37: 1137-1144.
11. Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R, LaSalle JM. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J 2001; 7: 395-403.
12. Dai B, Kong YY, Ye DW, Ma CG, Zhou XY, Yao XD. Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy. Asian J Androl 2008; 10: 701-709.
13. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002; 160: 339-345.
14. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001; 116: 234-239.
15. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-1925.